Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hurricane Sandy Rains On User Fee Dates, Advisory Committees

Executive Summary

FDA will extend user fee goal dates as needed to account for the loss of two days in review cycles resulting from the government office shutdown. The extreme weather conditions led to cancellation of three advisory committees during the week of Oct. 29.

You may also be interested in...



Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm

FDA postpones Feb. 13 advisory committee review of heart failure drug due to “unanticipated weather conditions” expected for the Washington, D.C. area, although the cardio-renal panel’s meeting on The Medicines Co.’s cangrelor will proceed as planned Feb. 12.

GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte

FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.

Zogenix’s Stand-alone Hydrocodone To Stand Before Advisory Panel

If approved, Zohydro will be the first extended-release version of hydrocodone and the first not to be combined with other painkillers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel